| For: | Kruis W, Jessen P, Morgenstern J, Reimers B, Müller-Grage N, Bokemeyer B. Shared decision-making improves adherence to mesalamine in ulcerative colitis: A prospective, multicenter, non-interventional cohort study in Germany. World J Gastroenterol 2025; 31(22): 101915 [PMID: 40539204 DOI: 10.3748/wjg.v31.i22.101915] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v31/i22/101915.htm |
| Number | Citing Articles |
| 1 |
Christina Golna, Chara Tzavara, Pavlos Golnas, Aikaterini Nikitara, Maria Nomikou, George Kapetanakis, Emilia Daghir – Wojtkowiak, Katarzyna Barud, Syed Zulkifil Haider Shah, Alexander Laird, Javier Alfaro, Fabio Massimo Zanzotto, Maria Gazouli, Kyriakos Souliotis. Patient perspectives on the use of artificial intelligence to support treatment decision making in renal cancer: findings from the KATY project. BMC Medical Informatics and Decision Making 2026; 26(1) doi: 10.1186/s12911-026-03457-6
|
| 2 |
Jian Liu, Xiaoyun Kang, Yanxiang Zhou, Jiao Li. A lactylation modification-related prediction model for the diagnosis of ulcerative colitis based on machine learning. Frontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1717232
|
| 3 |
Kerry A. Ryan, Kelcie K. Darpel, Joel H. Rubenstein, Evan S. Dellon, Lauren P. Wallner, Raymond De Vries, Joy W. Chang, Akif Altınbas. Shared decision making in Eosinophilic esophagitis: Integrating physician and patient perspectives. PLOS One 2026; 21(6) doi: 10.1371/journal.pone.0350662
|
| 4 |
Reid Herran, Samuel Wilcox, Gal Hodish, Syed A. Hassan, Haley Mertens, Christopher V. Almario, Philip Gu, Maia Kayal, Shirley Cohen-Mekelburg, Randolph E. Regal, Shrinivas Bishu, Corey A. Siegel, Melissa DeJonckheere, Peter D. R. Higgins, Jeffrey A. Berinstein. Navigating Treatment Selection in Acute Severe Ulcerative Colitis: A Prospective Mixed Method Analysis of Factors Influencing Patient Decision-Making. Digestive Diseases and Sciences 2026; doi: 10.1007/s10620-026-10046-0
|
| 5 |
Bolette Christophersen, John Fullarton, Rachel West. Optimised mesalazine therapy reduces ulcerative colitis recurrence across the mild-to-moderate disease spectrum: the IMPACT study. Frontiers in Gastroenterology 2026; 5 doi: 10.3389/fgstr.2026.1874051
|